Use of recombinant parainfluenza viruses (PIVs) as vectors to protect against infection and disease caused by PIV and other human pathogens

US7192593B2 · kind B2 · utility

Assignee

• THE UNITED STATES OF AMERICA, represented by the Secretary, Department of Health and Human Services · US

Inventors

• Brian R. Murphy · Bethesda, US
• Peter L. Collins · Kensington, US
• Alexander C. Schmidt · Washington, US
• Anna P. Durbin · Takoma Park, US
• Mario H. Skiadopoulos · Potomac, US
• Tao Tao · Bethesda, US

Key dates

• Filing date: Dec 8, 2000
• Grant date: Mar 20, 2007
• Expiry date: Dec 8, 2020

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2760/18643
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Chimeric parainfluenza viruses (PIVs) incorporate a PIV vector genome or antigenome and one or more antigenic determinant(s) of a heterologous PIV or non-PIV pathogen. These chimeric viruses are infectious and attenuated in humans and other mammals and are useful in vaccine formulations for eliciting an immune responses against one or more PIVs, or against a PIV and non-PIV pathogen. Also provided are isolated polynucleotide molecules and vectors incorporating a chimeric Ply genome or antigenome which includes a partial or complete PIV vector genome or antigenome combined or integrated with one or more heterologous gene(s) or genome segment(s) encoding antigenic determinant(s) of a heterologous PIV or non-PIV pathogen.